Transplant candidates January 1, 2015 to December 31, 2017 | HR | p-value | |||
All patients | Patients with NAFLD | Patients without NAFLD | |||
Subjects n | 150 | 40 | 110 | ||
Age years (median/interquartile range) | 63.4 (55.7–66.9) | 58.8 (48.9–65.9) | 1.87 | 0.06 | |
Female | 65 (43) | 13 (33) | 52 (47) | 0.14 | |
BMI (median/interquartile range) | 29.1 (26.7–31.1) | 25.5 (22.7–28.9) | 3.53 | < 0.01 | |
Underlying diagnosis | 0.02 | ||||
Obstructive | 46 (31) | 8 (20) | 38 (35) | ||
Emphysema | 7 | 21 | |||
A1AT-deficiency | 1 | 6 | |||
Bronchiectasis | 0 | 6 | |||
Bronchiolitis | 0 | 5 | |||
Pulmonary vascular | 5 (3) | 0 | 5 (5) | ||
Cystic fibrosis | 17 (11) | 2 (5) | 15 (14) | ||
Interstitial lung disease | 82 (55) | 30 (75) | 52 (47) | ||
IPF | 17 | 29 | |||
NSIP | 2 | 1 | |||
HP | 1 | 2 | |||
PF | 7 | 17 | |||
BOOP/COP | 2 | 1 | |||
Sarcoid | 1 | 1 | |||
LAM | 0 | 1 | |||
Lung allocation score (median/interquartile range) | 38.2 (34.6–45.6) | 38.6 (33.5–51.9) | −0.45 | 0.66 | |
Pre-transplant 6-min walk distance feet (median/interquartile range) | 808 (713–1146) | 859 (659–1122) | −0.24 | 0.81 | |
Pre-transplant diabetes | 29 (19) | 7 (18) | 22 (20) | 0.82 | |
Pre-transplant hypertension | 72 (65) | 22 (55) | 50 (46) | 0.36 | |
Pre-transplant hyperlipidaemia | 59 (41) | 21 (53) | 38 (35) | 0.06 | |
Allograft ischaemic time minutes (median/interquartile range) | 257 (224–316) | 261 (208–317) | −0.12 | 0.90 | |
CMV serologic mismatch (D+/R−) | 44 (29) | 13 (33) | 31 (28) | 0.69 |
Data expressed as n (%) unless otherwise indicated. NAFLD: non-alcoholic fatty liver disease; BMI: body mass index; IPF: idiopathic pulmonary fibrosis; NSIP: nonspecific interstitial pneumonia; HP: hypersensitivity pneumonitis; PF: pulmonary fibrosis; BOOP/COP: bronchiolitis obliterans organising pneumonia/crytpogenic organising pneumonia; LAM: lymphangioleiomyomatosis; CMV: cytomegalovirus.